It is over twenty years since cisplatin was first given to cancer patients, and a decade since
the initiation of clinical trials of carboplatin. Nevertheless, platinum-based cancer therapy …

The vast amount of basic research on platinum coordination complexes has produced, over
the past 25 years, several thousand new molecules for preclinical screening and 28 …

Over the past two decades, platinum-based drugs (cis-platin and, latterly, the less toxic
analogue carboplatin) have conferred significant therapeutic benefit to a large number of …

[PrClfiH J2]) has improved substantially the response rate5 in a number of malignant
conditions, particularly testicular and ovarian cancer. However, the clinical utility of the drug …

The platinum-based drugs, cisplatin and carboplatin, represent major agents in the
chemotherapeutic treatment of a variety of types of cancer. Novel," third-generation" agents …

Cisplatin, carboplatin and oxaliplatin continue to be among the most efficient anticancer
drugs in world-wide clinical use so far. In particular, cisplatin has shown a remarkable …

It all started with an accidental discovery in the laboratory of Dr. Barnet Rosenberg at
Michigan State University in the mid 1960s. Now, thirty years from the landmark publication …

During the past 3 years, eight hospitals and one cooperative study group have reported their
initial clinical results with cis-dichlorodiammineplatinum (II). The most popular clinical …

Chemotherapy is one of the main weapons in the fight against cancer. Until recently the
majority of antitumor drugs were organic compounds or natural products including alkylating …

The limitations of cisplatin as an anticancer drug have stimulated the search for other
antitumor-active platinum complexes with improved pharmacological properties. The two …